Valeant a Step Closer to Medicis - Analyst Blog

By Zacks Equity Research,

Shutterstock photo

Valeant Pharmaceuticals International, Inc. ( VRX ) is a step closer to acquiring Medicis Pharmaceutical Corp. ( MRX ) with theUS Federal Trade Commission granting the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.

Valeant Pharma had announced its intention to acquire specialty pharmaceutical company, Medicis Pharma in September 2012. The companies signed a definitive merger agreement under which Valeant Pharma will acquire Medicis Pharma for $44.00 per share in cash. The deal is expected to be worth approximately $2.6 billion.

On December 7, 2012, a special meeting will be held for Medicis Pharma's shareholders. The stockholders will vote on the acquisition proposal. The deal is expected to close within four business days following the satisfaction of all closing terms and conditions. At the time of announcing the deal, Valeant Pharma stated that the acquisition is expected to boost its earnings immediately after the closure.

We note that Medicis Pharma is engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the US. Key products include Solodyn, Perlane, Restylane, Ziana, Dysport and Zyclara. The impending merger will broaden Valeant Pharma's product portfolio significantly and is expected to create a global leader in the dermatological field.  

We note that the dermatological segment has been in the spotlight this year. Apart from Valeant Pharma's impending acquisition of Medicis Pharma, the acquisition of specialty dermatology generics company, Fougera Pharma by Novartis ( NVS ) in July 2012, has also been in the news. Moreover, Allergan, Inc. ( AGN ) recently announced that it has entered into an agreement with a privately held company, SkinMedica, Inc. to acquire the latter's topical aesthetics skin care business.

Our Recommendation

We currently have an Outperform recommendation on Valeant Pharma. The stock carries a Zacks #1 Rank (Strong Buy rating) in the short run.

ALLERGAN INC (AGN): Free Stock Analysis Report

MEDICIS PHARM-A (MRX): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

VALEANT PHARMA (VRX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
Referenced Stocks: AGN , MRX , NVS , VRX

More from


Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by